<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Sionna Therapeutics, Inc. Common Stock — News on 6ix</title>
    <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock</link>
    <description>Latest news and press releases for Sionna Therapeutics, Inc. Common Stock on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/sionna-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c01478dffbe2df118566.webp</url>
      <title>Sionna Therapeutics, Inc. Common Stock</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock</link>
    </image>
    <item>
      <title>Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-completes-enrollment-in-precision-cf-phase-2a-trial-evaluating-nbd1-stabilizer-sion-719-added-to-standard-of-care-in-participants-with-cystic-fibrosis</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-completes-enrollment-in-precision-cf-phase-2a-trial-evaluating-nbd1-stabilizer-sion-719-added-to-standard-of-care-in-participants-with-cystic-fibrosis</guid>
      <pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
      <description>Topline data is on track for anticipated readout in the summer of 2026WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced the completion of enrollment in the PreciSION CF Phase 2a proof-of-concept (POC) trial. This trial is evaluating SION-719, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, when</description>
    </item>
    <item>
      <title>Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-to-participate-in-the-raymond-james-2026-biotech-innovation-symposium</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-to-participate-in-the-raymond-james-2026-biotech-innovation-symposium</guid>
      <pubDate>Tue, 07 Apr 2026 11:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesda</description>
    </item>
    <item>
      <title>Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
      <description>Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis</description>
    </item>
    <item>
      <title>Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-to-participate-in-upcoming-march-2026-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-to-participate-in-upcoming-march-2026-investor-conferences</guid>
      <pubDate>Mon, 23 Feb 2026 13:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events: TD Cowen 46th Annual Health Care Con</description>
    </item>
    <item>
      <title>Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-present-guggenheim-securities-emerging-outlook-biotech-summit</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-present-guggenheim-securities-emerging-outlook-biotech-summit</guid>
      <pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to</description>
    </item>
    <item>
      <title>Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
      <pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to</description>
    </item>
    <item>
      <title>Sionna Therapeutics to Participate in Upcoming December Investor Conferences</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-participate-upcoming-december-investor-conferences-2025-11-24</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-participate-upcoming-december-investor-conferences-2025-11-24</guid>
      <pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to</description>
    </item>
    <item>
      <title>Sionna Therapeutics Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-reports-third-quarter-2025-financial-results-2025-11-05</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-reports-third-quarter-2025-financial-results-2025-11-05</guid>
      <pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
      <description>Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic</description>
    </item>
    <item>
      <title>Sionna Therapeutics to Participate in Upcoming November Investor Conferences</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-participate-upcoming-november-investor-conferences-2025-11-04</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-participate-upcoming-november-investor-conferences-2025-11-04</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to</description>
    </item>
    <item>
      <title>Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-announces-presentation-sion-719-and-sion-451-phase-1-data-and</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-announces-presentation-sion-719-and-sion-451-phase-1-data-and</guid>
      <pubDate>Fri, 24 Oct 2025 04:00:00 GMT</pubDate>
      <description>Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic</description>
    </item>
    <item>
      <title>Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-announces-initiation-precision-cf-phase-2a-trial-evaluating-nbd1</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-announces-initiation-precision-cf-phase-2a-trial-evaluating-nbd1</guid>
      <pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
      <description>SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025</description>
    </item>
    <item>
      <title>Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-present-data-2025-north-american-cystic-fibrosis-conference-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-present-data-2025-north-american-cystic-fibrosis-conference-2025</guid>
      <pubDate>Wed, 01 Oct 2025 04:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to</description>
    </item>
    <item>
      <title>Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-appoints-caroline-stark-beer-chief-business-officer-2025-09-08</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-appoints-caroline-stark-beer-chief-business-officer-2025-09-08</guid>
      <pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to</description>
    </item>
    <item>
      <title>Sionna Therapeutics to Participate in Upcoming September Investor Conferences</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-participate-upcoming-september-investor-conferences-2025-08-27</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-participate-upcoming-september-investor-conferences-2025-08-27</guid>
      <pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to</description>
    </item>
    <item>
      <title>Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-announces-first-subjects-dosed-phase-1-trial-evaluating-nbd1</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-announces-first-subjects-dosed-phase-1-trial-evaluating-nbd1</guid>
      <pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
      <description>Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026 WALTHAM,</description>
    </item>
    <item>
      <title>Sionna Therapeutics Reports Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-reports-second-quarter-2025-financial-results-2025-08-11</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-reports-second-quarter-2025-financial-results-2025-08-11</guid>
      <pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
      <description>Announced positive Phase 1 data for SION-719 and SION-451 demonstrating both first-in-class NBD1 stabilizers were generally well tolerated and exceeded</description>
    </item>
    <item>
      <title>Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-announces-presentation-preclinical-data-demonstrate-proprietary</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-announces-presentation-preclinical-data-demonstrate-proprietary</guid>
      <pubDate>Fri, 06 Jun 2025 04:00:00 GMT</pubDate>
      <description>Data featured in oral presentation and poster session at 48th European Cystic Fibrosis Conference WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Sionna</description>
    </item>
    <item>
      <title>Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-announces-positive-phase-1-data-nbd1-stabilizers-sion-719-and</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-announces-positive-phase-1-data-nbd1-stabilizers-sion-719-and</guid>
      <pubDate>Wed, 04 Jun 2025 04:00:00 GMT</pubDate>
      <description>SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to</description>
    </item>
    <item>
      <title>Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-present-goldman-sachs-46th-annual-global-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-present-goldman-sachs-46th-annual-global-healthcare-conference</guid>
      <pubDate>Tue, 03 Jun 2025 04:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to</description>
    </item>
    <item>
      <title>Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference</title>
      <link>https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-present-preclinical-data-during-oral-session-48th-european-cystic</link>
      <guid isPermaLink="true">https://6ix.com/company/sionna-therapeutics-inc-common-stock/news/sionna-therapeutics-present-preclinical-data-during-oral-session-48th-european-cystic</guid>
      <pubDate>Thu, 22 May 2025 04:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to</description>
    </item>
  </channel>
</rss>